Peripheral blood lymphocytes from some of patients with mycosis fungoides disease showed decreased ability to form rosettes with sheep erythrocytes_ This decreased ' percentage of E -rosette forming cells could be normalized when those cells were incubated in culture for 20 hr. Since these data led us to considering a possible inhibitory factor present in patients' sera, we tested their ability to inhibit E-rosetting by T lymphocytes from normal donors, and found that sera from mycosis fungoides patients with low levels of E -rosetting blood lymphocytes showed greater inhibitory effect on E-rosette formation by normal T cells when compared to those either from normal donors or from mycosis patients who had almost normal levels of E-rosetting blood lymphocyte number. The E -rosette inhibitory factor was sensitive to 2-mercaptoethanol treatment and was copurified with serum IgM by ammonium sulfate precipitation and by sequential gel filtrations, suggesting that it might be an anti-T lymphocyte antibody naturally occurring during the disease process.
It has been reported that mycosis fungoides (MF) is one of the T cell malignancies [1] [2] [3] , which usually undergoes 3 different stages, i.e., eczematous, plaque, and t umor stages. However, D'emblee type occurs at the tumor stage and has poorer rrognos is [4] . .
Recently, Nordqvist and Kinney [5] has reported t hat the MF patients have decreased percentage of peripheral blood lymphocytes (PBL) rosetting with sheep red cells (E). In t he present study, we have tested E-rosette formation ofPBL from the MF patients and have found that a certain serum factor might be responsible for the lowered number of E-rosetting PBL in the MF patients. This factor might be a naturally occuring anti-T cell antibody because it was sensitive to 2-mercaptoethanol treatment and was copurified with serum IgM by using ammonium sulfate precipitation and sequential gel filtrations.
.
MATERIALS AND METHODS

Patient Selection and S taging
Studies were performed in 5 MF patien ts vary ing in stages (Table I) 
Lymphocyte Separation
Mononuclear cells were separated from pe riph eral blood by centrifugation on a FicoLl-Conray gradient (d = 1.080) at 250 g for 20 min. Cells at the in terface were collected, washed 3 times with phosphatebuffered saline (PBS) and suspended in RPMI-1640 medium. More t han 98% of cells were viab le after wash ing, as determined by try pan blu e dye exclus ion test [6] .
E-rosette Formation
The ab ili ty of PBL to form spontaneous rosettes with neuraminidasetreated sheep E was examined by the method of Bentwich et al [7] . Briefly, equal volumes (0.1 ml) of 0.5% E a nd PBL (5 X IOG/ mI) were admixed and incubated at 37°C for 5 min. The mixture was then spu n at 200 g for 5 min and kept at 4°C for 1 hr. The cells were gently resuspe nded a nd the percentage of ce lls with more than 2 sheep E were coun ted.
E-rosette Inhibition T est
The ability of sera from MF patients to inhibi t E-rosette formation of PBL from normal donors was studied by the method previously described [8] . Briefly, 0.1 ml of normal PBL (5 X 10"/mI) was mixed with 0.1 ml of undiluted human sera or fractionated sera (20 mg protein/ ml) and incubated at 20°C for 30 min. T he cells were washed 3 t imes with PBS, suspended in 0. 1 ml of RPMI-1640 and mixed with 0.1 ml of 0.5% shee p E. The mixture was cen tri fuged a nd in cubated at 4°C for 1 hr. The numbers of E-rosettin g cells were co un ted, estimating t he percentage of E-rosette inhibition (%EI) as Untreated %RFC -Serum-treated %RFC Untreated %RFC X 100 (%)
Ammonium Sulfate Precipitation
S ix vo lu mes of human serum were admixed wi t h 4 vol of saturated ammoni um s ulfate solu tion (PH 7.0). Precipitates which contained gamma-globulin were co llected by centrifugation at 10,000 g for 15 min. The s upel'l1atant was co ll ected and dia lyzed agai nst PBS. The pellet was dissolved in an appropriate amo un t of PBS and reprecipitated with 40% NH"SO". The precipitates were dissolved in PBS and dialyzed against PBS for 24 111" in a cold room.
Treatment of Human Gamma-globulin with 2-merca.ptoethanol (2· ME)
Crude gamma-globulin (20 mg/ ml) prepa red by am moniu m sulfate precipi tation or undilu ted huma n serum was mixed with 2-ME to give a fmal co nce ntration of 0.05 M, which was a nontoxic dose for human PBL. After incubation at 20°C for 1 hr, 2-ME-treated samples were utilized for E-rosette inhibition ex periments.
Gel Filtration
A co lumn (1.8 X 50 cm) was prepared with either Bio-Gel A1.5m or Bio-Gel A5m (Bio-Rad Laboratories, Hichmond, Ca.) a nd eq uilibrated with a running buffer of PBS (PH 7.4). Descending chromatography was performed at 4°C with a flow rate of 2 mI/hr. The co lumn was calibrated for molecular weight estimation with purified human IgG, bovine serum a lbumin (BSA) and ovalbumin (OYA).
Cytotoxicity Test
Complement-dependent cytotoxicity was determined by trypan blue dye exclusion test using normal rabbit seru m as a so w'ce of complement [6] . Equal vo lumes of target T ce ll suspension (5 x lOG/mI), normal or MF patient's se rum and complement (C) were mixed and incubated at 37°C for 30 min. Lysed cells were judged by uptake of trypan blue, 
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" Case 1 was a 41 -yr-old ma le in t he tumor s tage, who had been considered to be a very rare case of D'emblee type. Case 2 was a 55-yr-old fema le also in the t umor stage. Case 3 was a 78-yr-old male in t he plaque stage at fU'st, followed by relatively rapid clinical course to reach finally t he tumor stage. Case 4 a nd 5 were in the tumor stage. Case 1 to 3 ha d a decreased percentage of E-rosetting PBL. (%E-RFC) when tested before chemothera py, whereas Case 4 and 5 showed almost normal %E-RFC in t he blood. T he form er patien ts have aU died in spite of chemo and radiothera py bu t th e latter pa tients are a ll alive with a ppropriate treatment.
" Whi te blood cells (WBC) were differentia ted morphologically into either lymphocytes (Lymph.) granulocytes (Gran.) or monocytes (Mono.). ,. Cutaneous delayed type hypersens it ivity reacti ons measm ed 48 hr after treating pat ients wi th purified prote in derivative (PPD) or with dinitrochlorobenzene (DNCB).
d Normal va lue of %E-RFC is 68% (±1O%). e N ot dete rmined.
estima ting t he cytotoxic index (CI) as % alive in C co ntrol -% alive in experiment 00 (" )
Protein-A Rosette Assay
Protein-A (Pharmacia Fine Chemicals, Uppsala, Sweden) was co upled to ra bbit red cells with chl'o mic chloride according to Johnson's m ethod [9] . T cells were purified from PBL of normal donors by Erosette depletion techn ique [10] . One hunw'ed ILl of T cell suspension (5 X lO';/ ml) were mixed with equal volume of IgM rich fraction (20 mg/ ml) se parated from MF patients' ser a by using ammonium sulfate precipitation a nd Bio-Gel Al.5m gel filtration and were incubated at 4°C for 1 hr. After washing 3 times with PBS, t he cells were suspended in 0.1 ml of RPMI-1 640 and mixed with rabbit anti-human IgM a ntiserum. The cells were incuba ted at 4°C for 30 min, washed 3 times wit h PBS a nd suspended in 0.1 ml of RPMI-1 64 0 medium. Equal volumes (0.1 ml) of t he ce ll slIspens ion a nd 1% indicator red cells coated with protein-A wer e then admixed and spun at 200 g for 5 min. After 30 min at 4°C, the cells were gently suspended a nd t he percentage of IgMbinding cells which were rosetted with ra bbit erythrocytes coated wit h protein-A was counted.
RESULTS
E-rosette Formation of PBL from MF Patients
PBL were collected from 5 MF patients and thei.r ability to form E-rosettes was compared before and after culturing them for 20 hr in RPMI-1640 medium with 10% fetal calf serum (FCS) . As can be seen in Table II , depressed E-rosetting ability of MF patients' PBL, especially those from case 1 to 3, had recovered after the cultivation, showing almost normal levels of %E-RFC.
Effect of S era from MF Patients on E-rosette Formation of Normal PBL
Since the data described above led us to consider a possible serum factor that can suppress E -rosette formation of human PBL, we tested the ability of MF patients' sera to interfere with E-rosette formation of PBL from allogeneic normal donors. Group A sera collected from MF patients (case 1-3) with low levels of %E -RFC showed E-rosette inhibition, whereas Group B sera obtained from MF patients (case 4 and 5) with almost normal levels of %E-RFC, as well as those from normal donors, had little effect on E-rosetting of normal PBL (Fig 1) .
E-rosetting ability of PBL and E -rosette inhibitory effect of MF sera were compared in a single patient (case 1) who was diagnosed as D'emblee type and had a fatal prognosis. Sera were collected sequentially from the patient and the %E-RFC of his PBL were counted simulta neously. As Fig 2 indicates , t h ere was an inverse correlation between %E-RFC of the patient's PBL and the a bility of the patient's serum to inhibit Erosette forma tion. " Percentage of E-rosetting lymphocytes in MF patients' blood was co unted before and after cultming t hose cells in t he presence of fetal calf serum.
Partial Purification of E-rosette Inhibitory Factor from MF S erum
Crude gamma-globulin fraction was prepared by 40% ammonium sulfate precipitation from MF and control normal human sera and its inhibitory effect on E-rosette formation of normal PBL was tested by E-rosette inhibition assay. While crude gamma-globulin fraction from normal human serum showed little effect on E-rosetting, the same fraction obtained from MF serum showed E-rosette inhibitory activity. This activity was lost when the gammaglobulin fraction ofMF serum was treated with 2-ME (Table III) .
The crude gamma-globulin fraction prepru'ed from MF serum by ammonium sulfate precipitation was then separated by BioGel A1.5m column chromatography into 2 different fractions (Fig 3) . As Table IV shows, E-rosette inhibitory activity was found in the fIrst fraction (F-1) but not in th e second fraction ofMF serum samples, whereas those fractions of normal huma n serum had no inhibitory activities. When those 2 fractions of MF serum were incubated with rabbit anti-human IgM and IgG sera in double immunodiffusion plates, we found t h at th e fIrst fraction contained IgM but not IgG, whereas the second fraction had IgG but not IgM (data not shown) .
In t h e next experiment, the fIrst fraction of Bio-Gel A1.5m effluent was further chromatograph ed by using Bio-Gel A5m column . As can be seen in Fig 4, t he column effluent was separated into 4 different fractions, which were tested for Erosette inhibitory activity a nd IgM content. Among t hese fractions, r elatively high E -rosette inhibition was observed wit h t h e second fraction (Table V) , where IgM was also copmifIed (Fig   5) .
Binding of IgM in MF Serum to T Cell Surfaces
If t he E-rosette inhibitory factor present in MF sera is an IgM antibody to human T cells, then one can expect t h at it migh t have cytotoxic effect on T cells. However, when we tested anti-T cell cytotoxic activity ofIgM rich fraction (F -1) separated . . from MF serum by using 40% NH.SO. precipitation and BioGel Al.5m gel filtration, its cytotoxic activity was low, showing less than 20% CI against human T cells (Table VI) .
Because of the insensitivity of cytotoxic testing, we then employed more sensitive technique for detecting IgM binding to human T cell surfaces. For this purpose, we used indirect protein-A rosette assay and could fmd that more than 40% of human T cells could specifically adhere to IgM from the fraction (F-l) separated from MF serum by ammonium sulfate precipitation a nd by Bio-Gel Al.5m filtration (Table VII) .
Vol. 76 "Hum an serum or its gamma-glob ulin fraction prepared by 40% ammonium sul fate saturation was incubated with normal hum an blood lymphocytes. The cells were then was hed a nd tested fo r their abil ity to form E-rosettes.
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Tube Number FIG 3 . E lu tion proftle of crude gamma-globulin precipitated from MF serum by 40% a mmonium sulfate saturation on Bio-Gel A1.5m ftItration. Two fractions (F-l , F-2) were co ll ected a nd subj ected to Erosette inhibition assay. "Crude gamma-globulin precipitated from human serum by 40% ammonium s ulfate saturation was further separated into 2 fractions (F-1, F-2) by Bio-Gel A1.5m co lumn.
"Normal human blood lymphocytes were incubated with eac h fract ion, washed and tested for their ab ili ty to form E -rosettes.
DISCUSSION
The possibility that a certain serum factor might be responsible for impaired E-rosette formation of T cells observed in MF patients [5] was suggested by the following observations; (1) depressed %E-RFC of MF patients' PBL could be normalized by culturing them for 20 hI"; (2) sera collected from MF patients suppressed E-rosette formation of PBL from normal donors. Moreover, we have noticed in this preliminary experi-
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ment that t here exists a inverse correlation between %E-RFC of PBL from MF patients and the ability of their sera to inhibit E-rosette formation of normal T cells. Thus, the sera from patients with low levels of %E-RFC showed greater E -rosette inhibitory activity than those sera collected from MF patients with almost normal levels of %E-RFC. This is also t he case in a single MF patient, whose sera were sequentially collected a nd E-rosette inhibitory activities were compar ed to %E-RFC of this patient's PBL at each time when the serum samples were collected. o "The fiest fraction (F-1) obtained from MF serum by B io-Gel A1.5m ftltration was further se parated into four different fractions by using Bio-Gel A5m column.
I, Normal blood T lymphocytes were incubated with each fraction, washed and tested for t heir ability to form E-rosettes. " F-1 fra ction was obtained from MF or normal serum by using 40% a mmonium sulfate saturation and Bio-Gel A1.5m gel fil trat ion.
"Percentage of Protein A rosette form ing cells (RFC) was subtracted by that of RFC treated with the second reagent (anti-IgM) a lone.
Defective E-rosette formation of T lymphocytes has been observed in association with a variety of diseases including cancer [11] , autoimmune disease [12] , viral infection [13] , sarcoidosis [14] and Hodgkin's disease [15] . In some of these cases, certain serum factors responsible for impaired E-rosette formation have been reported [13] [14] [15] . Thus, Chisari and Edgington [13] have reported t hat beta-lipoprotein of the low-density lipoproteins from sera of patients with hepatitis B has E-rosette inhibitory activity. Menzoian et aI [16] , on the other hand, have shown that immunoregulatory alpha-globulin can inhibit Erosetting by T cells. In contrast to these studies, it has also been reported that E-rosette inhibitory serum factors are present in the gamma-globulin fraction in cases of Hodgkin's disease [15] and sarcoidosis [14] . The latter observation seems to be similar to our data indicating that the E-rosette inhibitory factor found in MF patients' sera was 2-ME-sensitive and could be copurified with serum IgM by using ammonium sulfate precipitation and gel filtrations. This factor might be an IgM antibody to T cells occuring naturally during the disease process but it has low complement-dependent cytotoxicity unlike natural antithymocytotoxic antibody in SLE patients [12] or anti-T cell antibody found in sarcoidosis patients [14] . It is likely that E-rosette inhibitory fa ctors detected in different diseases are heterogeneous and participate in immune disfunction observed in such diseases.
The fact. that MF patients who had low %E-RFC and high Erosette inhibitory serum activity had poor prognosis, whereas those patients with normal levels of %E-RFC and little Erosette inhibitory serum activity had better clinical courses suggests t hat measuring the serum inhibitory factor in MF patients may provide a valuable tool for the confirmation of disease activity and prognosis in those patients. To confi.rm this possibility, further clinical study with a large number of MF patients is clearly required a nd the study is now being undertaken.
